Insulin vs Somatropin (recombinant hGH)

	Insulin FDA Approved	Somatropin (recombinant hGH) FDA Approved
Evidence rating	5/5 Very strong Evidence rating 5 out of 5: Very strong	5/5 Very strong Evidence rating 5 out of 5: Very strong
Regulatory status	Approved worldwide since 1923 and on the WHO Model List of Essential Medicines. Regulated in the US as a biologic since 2020, which opened a pathway for interchangeable biosimilars.	FDA-approved for growth hormone deficiency, Turner syndrome, Prader-Willi syndrome, short bowel syndrome and several other indications. Distribution for anti-aging use is specifically prohibited by US federal law.
Category	Metabolic & Weight	Growth Hormone Axis
Drug class	Endogenous 51-residue two-chain peptide hormone (A-chain 21 residues, B-chain 30 residues) joined by two interchain disulfide bridges; therapeutic versions are recombinant human insulin or analogues with residue substitutions that alter absorption rate	191-amino-acid recombinant human growth hormone — a protein, not a short peptide
Route	Subcutaneous injection or infusion; intravenous in hospital; one inhaled formulation	Subcutaneous, daily (or weekly for long-acting analogs)
Half-life	Rapid-acting analogues ~1 h subcutaneously (regular insulin ~1.5 h); degludec ~25 h at steady state, set by slow depot absorption and albumin binding.	~3–4 hours subcutaneously
Sequence length	51 residues	191 residues (protein)
Molecular weight	5,807.6 Da	22,124.8 Da
Studied in	Close to a century of randomized trials, registries and outcome studies. DCCT and its EDIC follow-up established that tight glycaemic control reduces microvascular complications in type 1 diabetes; UKPDS did the equivalent work in type 2. Analogue-versus-human-insulin trials consistently show fewer hypoglycaemic episodes rather than better HbA1c.	Decades of randomized trials across pediatric and adult deficiency states; large post-marketing safety registries such as KIGS and NordiNet.
Who should avoid it	Anyone without a diagnosis requiring it — there is no non-diabetic use of insulin that is not dangerous Use for muscle gain or body composition Any use not directed and monitored by a prescriber	Active malignancy Acute critical illness — a trial in ICU patients found increased mortality Proliferative diabetic retinopathy Closed epiphyses when used for height Anti-aging or performance use
Legal status	Prescription-only in essentially every jurisdiction, though some US states permit emergency pharmacist dispensing. Not available as a research chemical and not a supplement.	Prescription drug. US federal law (21 U.S.C. § 333(e)) prohibits distribution for any use other than approved indications, making anti-aging distribution a criminal offence.

Benefits — Insulin

Life-sustaining in type 1 diabetes
This is not a benefit in the sense the rest of this site uses the word. Without exogenous insulin, type 1 diabetes is fatal within weeks. No other entry in this library carries evidence of that character.
Reduces microvascular complications
DCCT/EDIC showed that intensive control cuts retinopathy, nephropathy and neuropathy, and that the benefit persists for decades after the trial period — the "metabolic memory" effect.
Effective at any stage of type 2 diabetes
Unlike agents that depend on residual beta-cell function, insulin works when the pancreas no longer does. It has no ceiling dose in the way oral agents do.
Analogues reduce hypoglycaemia versus human insulin
Long-acting analogues produce flatter profiles and consistently fewer nocturnal hypoglycaemic events, though the HbA1c difference is small.

Benefits — Somatropin (recombinant hGH)

Restores growth in deficient children
Unambiguous, dose-dependent improvement in growth velocity and final adult height — the indication it was developed for.
Body composition in adult deficiency
Reduces fat mass and increases lean mass in genuine adult GH deficiency, with improved quality-of-life scores.
Bone density improvement
Increases bone mineral density over multi-year treatment in deficient adults.
Multiple rare disease indications
Turner syndrome, Prader-Willi syndrome, SHOX deficiency and others, each with dedicated trial evidence.

Risks & cons — Insulin

Hypoglycaemia, including severe and fatal
The dose-limiting risk and the reason insulin appears on every "high-alert medication" list. Severe hypoglycaemia causes seizures, coma and death, and repeated episodes blunt the warning symptoms that would otherwise prevent the next one.
Deliberate misuse for physique or weight control
Insulin is used non-medically as an anabolic in bodybuilding and is omitted or underdosed by some people with diabetes to lose weight. Both practices have killed people. This site will not describe either.
Weight gain
Insulin is anabolic. Starting it typically adds 2–4 kg, which in type 2 diabetes can work against the underlying problem.
Dosing and product confusion
Concentrated formulations, similar trade names and unit-versus-millilitre errors are a recurring source of serious medication error, including in hospitals.
Injection site lipohypertrophy
Repeated injection into the same site produces fatty lumps that absorb insulin erratically, which is a common and under-recognised cause of unexplained glucose swings.

Risks & cons — Somatropin (recombinant hGH)

Distributing it for anti-aging is a federal crime in the US
GH is unusual: federal law restricts distribution to approved indications specifically, and prosecutions of anti-aging clinics have followed. This is not a grey area.
Insulin resistance and diabetes
GH is directly counter-regulatory to insulin. New-onset type 2 diabetes is a recognised consequence of sustained therapy.
Fluid retention, arthralgia and carpal tunnel
Dose-related and common in adults, sometimes limiting treatment.
Intracranial hypertension
Uncommon but serious; presents with headache and visual change and requires prompt assessment.
Slipped capital femoral epiphysis in children
A recognised orthopedic complication requiring surveillance during pediatric treatment.

Infographic for Somatropin (recombinant hGH)

A comparison is not a recommendation. Neither column is being suggested for you. Which — if either — is appropriate depends on your diagnosis, history and medications, and that is a conversation for a qualified clinician.